D-Glucosamine hydrochloride (GlcN？HCl) is an endogenous amino monosaccharide synthesized from glucose that is useful in the treatment of joint diseases in both humans and animals. The aim of this study was to examine amino acid metabolism in dogs after oral administration of GlcN？HCl. Accelerated fumarate respiration and elevated plasma levels of lactic acid and alanine were observed after administration. These results suggest that oral administration of GlcN？HCl induces anaerobic respiration and starvation in cells, and we hypothesize that these conditions promote cartilage regeneration. Further studies are required to evaluate the expression of transforming growth factor-beta (TGF-β).
References
[1]
Fox, B.A.; Stephens, M.M. Glucosamine hydrochloride for the treatment of osteoarthritis symptoms. Clin. Interv. Aging 2007, 2, 599–604.
[2]
Aghazadeh-Habashi, A.; Jamali, F. The glucosamine controversy; a pharmacokinetic issue. J. Pharm. Pharm. Sci. 2011, 14, 264–273.
[3]
Clegg, D.O.; Reda, D.J.; Harris, C.L.; Klein, M.A.; O’Dell, J.R.; Hooper, M.M.; Bradley, J.D.; Bingham, C.O., III.; Weisman, M.H.; Jackson, C.G.; et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 2006, 354, 795–808, doi:10.1056/NEJMoa052771.
[4]
Goodrich, L.R.; Nixon, A.J. Medical treatment of osteoarthritis in the horse—a review. Vet. J. 2006, 171, 51–69, doi:10.1016/j.tvjl.2004.07.008.
[5]
Minami, S.; Hata, M.; Tamai, Y.; Hashida, M.; Takayama, T.; Yamamoto, S.; Okada, M.; Funatsu, T.; Tsuka, T.; Imagawa, T.; et al. Clinical application of D-glucosamine and scale collagen peptide on canine and feline orthopedic diseases and spondylitis deformans. Carbohydr. Polym. 2010, 84, 831–834.
Aghazadeh-Habashi, A.; Sattari, S.; Pasutto, F.; Jamali, F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J. Pharm. Pharm. Sci. 2002, 5, 181–184.
[8]
Adebowale, A.; Du, J.; Liang, Z.; Leslie, J.L.; Eddington, N.D. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm. Drug Dispos. 2002, 23, 217–225, doi:10.1002/bdd.315.
[9]
Du, J.; White, N.; Eddington, N.D. The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharm. Drug Dispos. 2004, 25, 109–116, doi:10.1002/bdd.392.
[10]
Laverty, S.; Sandy, J.D.; Celeste, C.; Vachon, P.; Marier, J.F.; Plaas, A.H. Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum. 2005, 52, 181–191, doi:10.1002/art.20762.
[11]
Meulyzer, M.; Vachon, P.; Beaudry, F.; Vinardell, T.; Richard, H.; Beauchamp, G.; Laverty, S. Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulfate or glucosamine hydrochloride. Osteoarthr. Cartil. 2008, 16, 973–979.
[12]
Setnikar, I.; Giachetti, C.; Zanolo, G. Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of [14C] glucosamine to the rat. Pharmatherapeutica 1984, 3, 538–550.
[13]
Azuma, K.; Osaki, T.; Tsuka, T.; Imagawa, T.; Okamoto, Y.; Takamori, Y.; Minami, S. Effects of oral glucosamine hydrochloride administration on plasma free amino acid concentrations in dogs. Mar. Drugs 2011, 9, 712–718, doi:10.3390/md9050712.
[14]
Tamai, Y.; Miyatake, K.; Okamoto, Y.; Takamori, Y.; Sakamoto, H.; Minami, S. Enhanced healing of cartilaginous injuries by glucosamine hydrochloride. Carbohydr. Polym. 2002, 48, 369–378, doi:10.1016/S0144-8617(01)00281-8.
[15]
Tamai, Y.; Miyatake, K.; Okamoto, Y.; Takamori, Y.; Sakamoto, K.; Minami, S. Enhanced healing of cartilaginous injuries by N-acetyl-D-glucosamine and glucuronic acid. Carbohydr. Polym. , 54, 251–262.
[16]
Ringnér, M. What is principal component analysis? Nat. Biotechnol. 2008, 26, 303–304, doi:10.1038/nbt0308-303.
[17]
Simon, R.R.; Marks, V.; Leeds, A.R.; Anderson, J.W. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab. Res. Rev. 2011, 27, 14–27, doi:10.1002/dmrr.1150.
[18]
Kita, K.; Hirawake, H.; Miyadera, H.; Amino, H.; Takeo, S. Role of complex II in anaerobic respiration of the parasite mitochondria from Ascaris suum and Plasmodium falciparum. Biochim. Biophys. Acta 2002, 1553, 123–139.
[19]
Hirayama, A.; Kami, K.; Sugimoto, M.; Sugawara, M.; Toki, N.; Onozuka, H.; Kinoshita, T.; Saito, N.; Ochiai, A.; Tomita, M.; et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 2009, 69, 4918–4925.
[20]
Yalamanchi, N.; Klein, M.B.; Pham, H.M.; Longaker, M.T.; Chang, J. Flexor tendon wound healing in vitro: Lactate up-regulation of TGF-beta expression and functional activity. Plast. Reconstr. Surg. 2004, 113, 625–632, doi:10.1097/01.PRS.0000101529.47062.34.
[21]
Folkman, J.; Klagsbrun, M. Angiogenic factors. Science 1987, 235, 442–447.
[22]
Klein, M.B.; Yalamanchi, N.; Pham, H.; Longaker, M.T.; Chang, J. Flexor tendon healing in vitro: Effects of TGF-beta on tendon cell collagen production. J. Hand Surg. Am. 2002, 27, 615–620, doi:10.1053/jhsu.2002.34004.
[23]
Felig, P. The glucose-alanine cycle. Metabolism 1973, 22, 179–207, doi:10.1016/0026-0495(73)90269-2.
[24]
Cheatham, B. Enough is enough: Nutrient sensors and insulin resistance. Endocrinology 2004, 145, 2115–2117, doi:10.1210/en.2004-0146.
[25]
Uldry, M.; Ibberson, M.; Hosokawa, M.; Thorens, B. GLUT2 is a high affinity glucosamine transporter. FEBS Lett. 2002, 524, 199–203, doi:10.1016/S0014-5793(02)03058-2.
[26]
Luo, B.; Soesanto, Y.; McClain, D.A. Protein modification by O-linked GlcNAc reduces angiogenesis by inhibiting Akt activity in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 651–657, doi:10.1161/ATVBAHA.107.159533.
[27]
Soga, T.; Heiger, D.N. Amino acid analysis by capillary electrophoresis electrospray ionization mass spectrometry. Anal. Chem. 2000, 72, 1236–1241, doi:10.1021/ac990976y.
[28]
Soga, T.; Ohashi, Y.; Ueno, Y.; Naraoka, H.; Tomita, M.; Nishioka, T. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J. Proteome Res. 2003, 2, 488–494, doi:10.1021/pr034020m.
[29]
Soga, T.; Ueno, Y.; Naraoka, H.; Ohashi, Y.; Tomita, M.; Nishioka, T. Simultaneous determination of anionic intermediates for Bacillus subtilis metabolic pathways by capillary electrophoresis electrospray ionization mass spectrometry. Anal. Chem. 2002, 74, 2233–2239, doi:10.1021/ac020064n.
[30]
Soga, T.; Ishikawa, T.; Igarashi, S.; Sugawara, K.; Kakazu, Y.; Tomita, M. Analysis of nucleotides by pressure-assisted capillary electrophoresis-mass spectrometry using silanol mask technique. J. Chromatogr. 2007, 1159, 125–133.
[31]
Sugimoto, M.; Hirayama, A.; Ihiskawa, T.; Baran, R.; Robert, M.; Uehara, K.; Soga, T.; Tomita, M. Differential metabolomics software for capillary electrophoresis-mass spectrometry data analysis. Metabolomics 2010, 6, 27–41, doi:10.1007/s11306-009-0175-1.
[32]
Junker, B.H.; Klukas, C.; Schreiber, F. VANTED: A system for advanced data analysis and visualization in the context of biological networks. BMC Bioinforma. 2006, 7, doi:10.1186/1471-2105-7-109.
[33]
Klukas, C.; Schreiber, F. Integration of -omics data and networks for biomedical research with VANTED. J. Integr. Bioinform. 2010, 7, 112.
